More Big Pharma Players Have Access Plans For Poorer Countries
GSK Tops Access to Medicine Index Again
The notion that pharma R&D caters for western populations first and only much later are the fruits of that research made available for low-income countries is slowly but surely changing, according to a high-profile review of access to drugs.
